CTI Biopharma Corp CTIC:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 8:17 AM EDT
4.61quote price arrow up+0.11 (+2.44%)
Volume
12,658
Close
4.50quote price arrow up+0.30 (+7.14%)
Volume
3,302,891
52 week range
1.43 - 5.76
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.50
  • 52 Week High5.76
  • 52 Week High Date05/04/22
  • 52 Week Low1.43
  • 52 Week Low Date12/02/21

Key Stats

  • Market Cap490.37M
  • Shares Out108.97M
  • 10 Day Average Volume4.11M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change81.45

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.50
  • 52 Week High5.76
  • 52 Week High Date05/04/22
  • 52 Week Low1.43
  • 52 Week Low Date12/02/21
  • Market Cap490.37M
  • Shares Out108.97M
  • 10 Day Average Volume4.11M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change81.45

RATIOS/PROFITABILITY

  • EPS (TTM)-1.22
  • P/E (TTM)-3.70
  • Fwd P/E (NTM)-4.80
  • EBITDA (TTM)-94.806M
  • ROE (TTM)-447.11%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)80.74%
  • Net Margin (TTM)-1,940.54%
  • Debt To Equity (MRQ)1,257.76%

EVENTS

  • Earnings Date08/03/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On CTI Biopharma Corp

There is no recent news for this security.

Profile

MORE
CTI BioPharma Corp. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, IRAK1, FLT3 and CSF1R for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is...
Laurent Fischer M.D.
Non-Executive Independent Chairman of the Board
Adam Craig M.D., Ph.D.
President, Chief Executive Officer, Interim Chief Medical Officer, Director
Bruce Seeley
Chief Operating Officer, Executive Vice President
David Kirske
Chief Financial Officer, Executive Vice President, Secretary
Address
3101 Western Ave Ste 800
Seattle, WA
98121-3017
United States

Top Peers

SYMBOLLASTCHG%CHG
AUTL
Autolus Therapeutics PLC
2.72+0.35+14.77%
RAPT
Rapt Therapeutics Inc
13.75-0.66-4.58%
VXRT
Vaxart Inc
3.13-0.21-6.29%
FHTX
Foghorn Therapeutics Inc.
11.27+1.02+9.95%
KNTE
Kinnate Biopharma Inc
10.10+0.85+9.19%